Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | LEADS: shedding light on early-onset Alzheimer’s disease

In this video, Melissa E Murray, PhD, Mayo Clinic, Jacksonville, FL, provides insights into the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS). This is a longitudinal, observational study enrolling cognitively impaired and normal individuals aged 40-65 to study the development of early-onset Alzheimer’s disease (AD). The study assesses clinical, imaging, biomarker, and genetic characteristics. While autosomal dominant cases with PSEN1/2 and APP mutations are relatively well studied, much remains unknown about sporadic early-onset AD. LEADS will bring together numerous sites internationally to track biomarkers in these individuals, gain a better understanding of the genetic and biological processes involved in sporadic cases, and to bring more awareness to early onset AD. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.